Vancomycine-d12 (TFA)

Vancomycin-d12 TFA is a deuterium labeled Vancomycin. Vancomycin is an antibiotic for the treatment of bacterial infections. It acts by inhibiting the second stage of cell wall synthesis of susceptible bacteria. Vancomycin also alters the permeability of the cell membrane and selectively inhibits ribonucleic acid synthesis[1][2][3].

12352005

Antibiotic; Autophagy; Bacterial; Isotope-Labeled Compounds

Anti-infection; Autophagy; Others

COVID-19-immunoregulation

Cancer; Infection

O[C@@H]1[C@@H](O[C@@](O[C@@H](C)[C@H]2O)([H])C[C@@]2(N)C)[C@@H](O[C@H](CO)[C@H]1O)OC3=C(OC4=CC=C([C@H]([C@H]5NC(C(NC([2H])[2H])([2H])C([2H])([2H])C(C([2H])([2H])[2H])([2H])C([2H])([2H])[2H])=O)O)C=C4Cl)C=C([C@](NC([C@@H](NC5=O)CC(N)=O)=O)([H])C(N[C@](C6=O)([H])C7=CC8=C(O)C=C7)=O)C=C3OC9=CC=C([C@H]([C@](C(N[C@@](C(O)=O)([H])C%10=C8C(O)=CC(O)=C%10)=O)([H])N6)O)C=C9Cl.OC(C(F)(F)F)=O

C68H64D12Cl2F3N9O26

1575.35

[1]Rybak MJ, et al. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006 Jan 1;42 Suppl 1:S35-9. |[2]Watanakunakorn C, et al. Mode of action and in-vitro activity of vancomycin. J Antimicrob Chemother. 1984 Dec;14 Suppl D:7-18. |[3]Warren CA, et al. Vancomycin treatment's association with delayed intestinal tissue injury, clostridial overgrowth, and recurrence of Clostridium difficile infection in mice. Antimicrob Agents Chemother. 2013 Feb;57 (2) :689-96.

Room temperature

http://file.medchemexpress.com/batch_PDF/HY-B0671S/

Isotope-Labeled Compounds

No Development Reported